MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMA
The purpose of the study was to evaluate the relationship between the levels of transcription factor, vascular endothelial growth factor (VEGF), serine/threonine-protein kinase (m-TOR), proteasome and calpain activities and the response to everolimus therapy in patients with disseminated renal cell...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-07-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/332 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849253131530010624 |
|---|---|
| author | Z. А. Yurmazov L. V. Spirina Е. А. Usynin I. V. Kondakova Е. М. Slonimskaya |
| author_facet | Z. А. Yurmazov L. V. Spirina Е. А. Usynin I. V. Kondakova Е. М. Slonimskaya |
| author_sort | Z. А. Yurmazov |
| collection | DOAJ |
| description | The purpose of the study was to evaluate the relationship between the levels of transcription factor, vascular endothelial growth factor (VEGF), serine/threonine-protein kinase (m-TOR), proteasome and calpain activities and the response to everolimus therapy in patients with disseminated renal cell carcinoma. Material and methods. The study included 18 patients with disseminated renal cell carcinoma. The expression of transcription and growth factors was studied using an immune enzymatic assay. Proteasome and calpain activities were evaluated using a fluorometric method. Results. Partial regression and stable disease were observed in 14 (78.8 %) of patients (tumor regression in 22.2 % of patients, stable disease in 56.6 % of patients). Disease progression occurred in 4 (22.2 %) of cases. The objective response to therapy with m-TOR inhibitor was observed in patients with high levels of NF-κB and HIF-1transcription factors, VEGF, VEGFR2 as well as with increased proteasome activity before treatment. Treatment response was also associated with low expression of phospho-m-TOR protein kinase. Conclusion. Additional predictive molecular markers of response to targeted therapy with evorolimus were revealed. |
| format | Article |
| id | doaj-art-dad2f55ff6994a2899646c9b84d3fdb5 |
| institution | Kabale University |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2016-07-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-dad2f55ff6994a2899646c9b84d3fdb52025-08-20T03:56:27ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682016-07-01152424710.21294/1814-4861-2016-15-2-42-47325MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMAZ. А. Yurmazov0L. V. Spirina1Е. А. Usynin2I. V. Kondakova3Е. М. Slonimskaya4Tomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, RussiaTomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, Russia Siberian State Medical University, TomskTomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, RussiaTomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, RussiaTomsk Cancer Research Institute, 5, Kooperativny Street, 634009-Tomsk, Russia Siberian State Medical University, TomskThe purpose of the study was to evaluate the relationship between the levels of transcription factor, vascular endothelial growth factor (VEGF), serine/threonine-protein kinase (m-TOR), proteasome and calpain activities and the response to everolimus therapy in patients with disseminated renal cell carcinoma. Material and methods. The study included 18 patients with disseminated renal cell carcinoma. The expression of transcription and growth factors was studied using an immune enzymatic assay. Proteasome and calpain activities were evaluated using a fluorometric method. Results. Partial regression and stable disease were observed in 14 (78.8 %) of patients (tumor regression in 22.2 % of patients, stable disease in 56.6 % of patients). Disease progression occurred in 4 (22.2 %) of cases. The objective response to therapy with m-TOR inhibitor was observed in patients with high levels of NF-κB and HIF-1transcription factors, VEGF, VEGFR2 as well as with increased proteasome activity before treatment. Treatment response was also associated with low expression of phospho-m-TOR protein kinase. Conclusion. Additional predictive molecular markers of response to targeted therapy with evorolimus were revealed.https://www.siboncoj.ru/jour/article/view/332evorolimus, hif-1 transcription factor, vegf, vegfr2, транскрипционный фактор hif-1, vegf, vegfr2, nf-κb transcription factor, m-tor, proteasomes, calpains, renal cell carcinoma |
| spellingShingle | Z. А. Yurmazov L. V. Spirina Е. А. Usynin I. V. Kondakova Е. М. Slonimskaya MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMA Сибирский онкологический журнал evorolimus, hif-1 transcription factor, vegf, vegfr2, транскрипционный фактор hif-1, vegf, vegfr2, nf-κb transcription factor, m-tor, proteasomes, calpains, renal cell carcinoma |
| title | MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMA |
| title_full | MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMA |
| title_fullStr | MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMA |
| title_full_unstemmed | MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMA |
| title_short | MOLECULAR MARKERS ASSOCIATED WITH THE RESPONSE TO THERAPY WITH EVEROLIMUS IN PATIENTS WITH RENAL CELL CARCINOMA |
| title_sort | molecular markers associated with the response to therapy with everolimus in patients with renal cell carcinoma |
| topic | evorolimus, hif-1 transcription factor, vegf, vegfr2, транскрипционный фактор hif-1, vegf, vegfr2, nf-κb transcription factor, m-tor, proteasomes, calpains, renal cell carcinoma |
| url | https://www.siboncoj.ru/jour/article/view/332 |
| work_keys_str_mv | AT zayurmazov molecularmarkersassociatedwiththeresponsetotherapywitheverolimusinpatientswithrenalcellcarcinoma AT lvspirina molecularmarkersassociatedwiththeresponsetotherapywitheverolimusinpatientswithrenalcellcarcinoma AT eausynin molecularmarkersassociatedwiththeresponsetotherapywitheverolimusinpatientswithrenalcellcarcinoma AT ivkondakova molecularmarkersassociatedwiththeresponsetotherapywitheverolimusinpatientswithrenalcellcarcinoma AT emslonimskaya molecularmarkersassociatedwiththeresponsetotherapywitheverolimusinpatientswithrenalcellcarcinoma |